公开(公告)号：US20230056619A1

公开(公告)日：2023-02-23

申请号：US17759128

申请日：2021-01-19

申请人： UNIVERSITE DE ROUEN-NORMANDIE ,  INSTITUT NATIONAL DES SCIENCES APPLIQUÉES DE ROUEN ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ECOLE NATIONALE SUPERIEURE D'INGENIEURS DE CAEN ,  UNIVERSITE DE CAEN NORMANDIE

发明人： Firas AYADI ,  Virginie NACHBAUR ,  Valérie PRALONG

IPC分类号： C22B26/12 ,  C22B3/16

摘要： The present invention is in the field of the extraction of lithium from a material comprising lithium and at least another metal. In particular, the invention concerns a process of extraction of lithium at least, from a material comprising lithium and at least another metal.

公开(公告)号：US11382894B2

公开(公告)日：2022-07-12

申请号：US16498807

申请日：2018-03-29

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE DE ROUEN NORMANDIE ,  UNIVERSITE DE PICARDIE JULES VERNE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN ,  CENTRE HOSPITALIER UNIVERSITAIRE D'AMIENS

发明人： Jeremy Bellien ,  Isabelle Six ,  Romuald Mentaverri ,  Said Kamel

IPC分类号： A61K31/41 ,  A61P9/10 ,  A61K31/198 ,  C12Q1/42

摘要： The inventors demonstrate that the phosphatase and hydrolase domains of soluble epoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.

公开(公告)号：US20200028316A1

公开(公告)日：2020-01-23

申请号：US16487792

申请日：2018-02-27

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DES SCIENCES APPLIQUEES - ROUEN ,  UNIVERSITE DE ROUEN NORMANDIE

发明人： Ammar HIDEUR ,  Adil HABOUCHA ,  Arnaud BULTEL ,  Said IDLAHCEN ,  Thomas GODIN

IPC分类号： H01S3/10 ,  H01S3/00 ,  H01S3/23

摘要： A laser source for emitting a group of pulses, includes a primary laser source suitable for emitting at least one primary laser pulse; at least one interferometer suitable for forming, from the primary laser pulse, a plurality of secondary laser pulses, each interferometer comprising at least one delay line allowing two secondary laser pulses to be temporally separated, by a delay comprised between 50 ps and 10 ns; and a single-mode amplifying optical fiber intended to receive the secondary laser pulses, in order to form as output a group of spatially superposed pulses.

公开(公告)号：US20180355316A1

公开(公告)日：2018-12-13

申请号：US15780877

申请日：2016-12-02

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE DE ROUEN-NORMANDIE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN ,  ETABLISSEMENT FRANCAIS DU SANG (EFS) ,  UNIVERSITE DE CAEN NORMANDIE ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE CAEN

发明人： Jean-Baptiste LATOUCHE ,  Brigitte LE MAUFF QUESTER ,  Olivier TOUTIRAIS

IPC分类号： C12N5/0783 ,  A61K35/17

CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K39/00 ,  A61K2039/5158 ,  C12N2501/51 ,  C12N2501/599 ,  C12N2502/1114 ,  C12N2502/1121

摘要： The present invention relates to method of amplifying a population of antigen-specific memory CD4+ T cells using artificial presenting cells expressing HLA class II molecules. In particular, the present invention relates to a method of amplifying a population of antigen-specific memory CD4+ T cells comprising the steps of i) providing a population of artificial antigen presenting cells consisting host cells that are genetically modified to stably express at least one MHC class II molecule along with at least one accessory molecule ii) loading the population of artificial antigen presenting cells of step i) with an amount of at least one antigen of interest and iii) coculturing the suitable population of a T cells with the population of artificial antigen presenting cells of step ii).

公开(公告)号：US20230013304A1

公开(公告)日：2023-01-19

申请号：US17780148

申请日：2020-11-30

申请人： UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE ,  INSERM ( INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE ROUEN-NORMANDIE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) ,  INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) ,  ECOLE NORMALE SUPERIEURE DE LYON ,  UNIVERSITE CLAUDE BERNARD LYON 1

发明人： Stéphane GERARD ,  Jean-Philippe BOUILLON ,  Abderrazzaq BENTAHER ,  Eric HENON ,  Jacky JACQUOT ,  Janos SAPI ,  Frédéric VELARD

IPC分类号： C07D237/14 ,  A61K31/501 ,  A61K45/06 ,  C07D409/06 ,  C07D401/04

摘要： The invention relates to compounds of Formula I: or pharmaceutically acceptable solvates thereof, as well as their use in the treatment and/or prevention of diseases or conditions associated with a dysfunction of CFTR channel activity, in particular cystic fibrosis.

公开(公告)号：US20220356445A1

公开(公告)日：2022-11-10

申请号：US17624584

申请日：2020-07-03

申请人： UNIVERSITE DE BORDEAUX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT D'OPTIQUE THEORIQUE ET APPLIQUEE ,  UNIVERSITE DE ROUEN-NORMANDIE ,  INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCE MEDICALE

发明人： MAXIME FEYEUX ,  KEVIN ALESSANDRI ,  MAGALIE LECOURTOIS ,  LAETITIA MIGUEL ,  PIERRE NASSOY ,  ANNE ROVELET LECRUX

IPC分类号： C12N5/0793

摘要： The present invention relates to a method for in-vitro production of mammalian neurons expressing the 6 isoforms of the Tau protein (2N4R, 1N4R, 0N4R, 2N3R, 1N3R, 0N3R), comprising a step of neuronal differentiation, in which cellular microcompartments are cultivated for a period of 5 weeks to 100 weeks, each one comprising a hollow hydro gel capsule surrounding post-mitotic neuronal cells and an extracellular matrix, the neuronal differentiation step being carried out in a bioreactor, the cellular microcompartments being kept in suspension in an enclosure of the bioreactor containing a neuronal differentiation medium.

公开(公告)号：US20220307012A1

公开(公告)日：2022-09-29

申请号：US17824063

申请日：2022-05-25

申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Universite de Rouen Normandie

发明人： Luca Grumolato

IPC分类号： C12N15/10 ,  C12Q1/6816

摘要： The instant invention relates to a method for labeling endonuclease-treated cells, comprising the steps of a) providing cells or a composition comprising cells; b) bringing into contact said cells or said composition with: —at least one endonuclease suitable for targeting a genomic region of interest in said cells, or a vector suitable for expressing said endonuclease in said cells; —at least one first nucleic acid suitable for introducing one or more silent mutation(s) in said genomic region by homology-directed repair (HDR), and optionally one or more non-silent mutation(s); and —at least one second nucleic acid suitable for introducing one or more silent mutation(s) in said genomic region by homology-directed repair (HDR), but distinct from the silent mutations of the first nucleic acid; thereby labeling endonuclease-treated cells.

公开(公告)号：US20200237736A1

公开(公告)日：2020-07-30

申请号：US16624985

申请日：2018-06-22

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE DE ROUEN NORMANDIE ,  ICAHN SCHOOL OF MEDICINE OF MOUNT SINAI

发明人： Luca GRUMOLATO ,  Alexis GUERNET ,  Stuart AARONSON ,  Youssef ANOUAR

IPC分类号： A61K31/44 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/506 ,  A61K39/395 ,  A61P35/00

摘要： The invention relates to methods for preventing or treating resistance to EGFR inhibitors in cancer patients. More particularly, after performing a screen for small molecules potentially capable of countering cancer resistance to EGFR TKI, inventors identified the multikinase inhibitor sorafenib, which has the property, in combination with EGFR TKI, to prevent the enrichment of tumor cells containing mutations responsible for NSCLC resistance to first and third generation EGFR TKI. These data indicate that this multikinase inhibitor can prevent resistance to several generations of EGFR TKI. These in vitro data were confirmed in an in vivo xenograft mouse model of NSCLC. Finally these data were reproduced in cancer cells using SC-1, a sorafenib analogue. Accordingly, the invention relates to a method of preventing and/or treating cancer resistance to treatment with an epidermal growth factor receptor (EGFR) inhibitor in a subject in need thereof comprising administering to the subject sorafenib drug or sorafenib analogue, alone or in combination with an EGFR inhibitor.

公开(公告)号：US20180195124A1

公开(公告)日：2018-07-12

申请号：US15738922

申请日：2016-06-22

申请人： Centre Hospitalier Universitaire De Rouen ,  Universite de Rouen Normandie ,  Institut National De La Sante Et De La Recherche Medicale (INSERM)

发明人： Bruno José Gonzalez ,  Stéphane Marret ,  Matthieu Jean Alexandre Lecuyer ,  Annie Laquerriere ,  Soumeya Bekri ,  Céline Lesueur ,  Sylvie Marguerite Alberte Jegou ,  Pascale Yvonne Joséphine Marcorelles

IPC分类号： C12Q1/6883 ,  G01N33/68

摘要： The present invention provides a method for the diagnosis of disorders caused by foetal alcohol syndrome, said method comprising the assaying of PLGF (placental growth factor).

公开(公告)号：US20210223191A1

公开(公告)日：2021-07-22

申请号：US17053518

申请日：2019-05-10

申请人： Universite de Rouen-Normandie

发明人： Gérard Coquerel ,  Simon Clevers

IPC分类号： G01N23/207 ,  G01N23/20016 ,  G01N23/20033 ,  G01N21/35

摘要： The present invention relates to a device for spectroscopic measurements, in particular X-ray diffraction (XRD), temperature-resolved second harmonic generation (TR-SHG) or infrared (IR) measurements, which prevents the formation of condensation (dew) or ice (frost) when carrying out spectroscopic measurements in sub-ambient temperature conditions and to a method of spectroscopic measurements with said device.